Medication info
Empagliflozin/Metformin Extended-Release Tablet 10/1000 mg (Empagliflozin, Metformin)

Empagliflozin/Metformin Extended-Release Tablet 10/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Pink oval extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501760 · Approved 2025.07.11 · Insurance code 643508940

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and extended-release metformin hydrochloride 2000 mg. This medicine should be taken with a meal once daily in the evening to reduce gastrointestinal adverse reactions caused by metformin. Take 1 tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this medicine whole without splitting, crushing, grinding, or chewing it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the substance excreted in the stool contains the active ingredient of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the initial recommended dose is a total daily dose of empagliflozin 10 mg and the patient's current dose of metformin. If empagliflozin 10 mg is well tolerated and additional blood glucose control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching to this medicine from combination therapy with empagliflozin and metformin should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. ⦁ When this medicine is administered concomitantly with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). Special populations Renal impairment Because dose adjustment may be needed based on renal function, assessment of renal function before and periodically during treatment with this medicine is recommended. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate the medicine well and do not have other conditions that may increase the risk of lactic acidosis, it may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine should be discontinued immediately. Older patients In patients 75 years of age or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Abnormal blood glucose control
  • Type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used as an adjunct to diet and exercise to improve blood glucose control in adults with Type 2 diabetes. It is particularly given to patients whose blood glucose is not adequately controlled, and caution is necessary when used in cases of confirmed cardiovascular disease. The combination of empagliflozin and metformin enhances blood glucose control and aids in diabetes management. Overall, it improves blood glucose levels in diabetic patients and is used in treatment.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and extended-release metformin hydrochloride 2000 mg. This medicine should be taken with a meal once daily in the evening to reduce gastrointestinal adverse reactions caused by metformin. Take 1 tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this medicine whole without splitting, crushing, grinding, or chewing it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the substance excreted in the stool contains the active ingredient of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the initial recommended dose is a total daily dose of empagliflozin 10 mg and the patient's current dose of metformin. If empagliflozin 10 mg is well tolerated and additional blood glucose control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching to this medicine from combination therapy with empagliflozin and metformin should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. ⦁ When this medicine is administered concomitantly with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). Special populations Renal impairment Because dose adjustment may be needed based on renal function, assessment of renal function before and periodically during treatment with this medicine is recommended. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate the medicine well and do not have other conditions that may increase the risk of lactic acidosis, it may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine should be discontinued immediately. Older patients In patients 75 years of age or older, renal function and the risk of volume depletion should be considered.

Precautions

This drug is used to assist blood glucose control in patients with Type 2 diabetes. It consists of two components, each of which acts on the kidneys to control blood glucose levels. However, several important precautions must be observed when taking this medication. First, this drug should not be administered to patients with impaired kidney function. This is because the medication can accumulate in the body and pose risks if kidney function is moderately or severely diminished. Second, it should also be avoided in cases of acute kidney injury, severe infections, heart failure, or other serious health conditions. Third, this medication can cause a severe side effect called lactic acidosis, which is a condition characterized by excessive buildup of lactic acid in the blood, leading to acidification. Though this side effect is very rare, it can be fatal; thus, immediate consultation with medical personnel is necessary if sudden muscle pain, difficulty breathing, weakness, or abdominal pain occurs. Fourth, when taken with insulin or sulfonylureas, there is an increased risk of hypoglycemia; therefore, careful observation of blood glucose levels is required when co-administering these medications. Fifth, this drug can increase the risk of urinary and genital infections, so prompt treatment is necessary if symptoms of infection appear. Sixth, if surgery or contrast imaging tests are scheduled, this medication should be discontinued 48 hours prior and resumed only after confirming normal kidney function. Seventh, it is safer for women who are pregnant or may become pregnant to avoid taking this medication. Eighth, elderly patients or those at risk of fluid loss should be especially cautious due to the risk of dehydration or hypotension. Ninth, it is advisable to avoid alcohol consumption while taking this medication, as alcohol can increase the risk of lactic acidosis. Finally, this medication should be swallowed whole, not crushed or chewed, and although the tablet shell may sometimes appear in stool, this is normal. Regular monitoring of kidney function and blood glucose status is important while taking this medication, and any abnormal symptoms should prompt immediate consultation with a physician.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decrease and deficiency of vitamin B12
  • ketoacidosis
  • lactic acidosis
  • nausea
  • vomiting
  • diarrhea
Show 159 more
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste abnormalities
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • difficulty urinating
  • interstitial nephritis
  • thirst
  • elevated serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • ketoacidosis
  • urosepticemia
  • pyelonephritis
  • rash
  • urticaria
  • angioedema
  • perineal necrosis
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colorectal bleeding
  • chronic gastritis
  • constipation
  • gastritis
  • abdominal discomfort
  • anal incontinence
  • dry mouth
  • gastrointestinal disturbances
  • gastroesophageal reflux disease
  • oral discomfort
  • salivary gland pain
  • headache
  • dizziness
  • positional vertigo
  • sensory impairment
  • drowsiness
  • facial paralysis
  • CNS-origin dizziness
  • memory impairment
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • drowsiness
  • myasthenia
  • chest discomfort
  • chest pain
  • fever
  • facial swelling
  • chills
  • strange feelings
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • weight loss
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • double vision
  • hypertension
  • insomnia
  • otalgia
  • positional vertigo
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • diabetic foot
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • discoid eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal abrasion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal crystal formation
  • retinal vein occlusion
  • lattice retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual sputum
  • cough
  • epistaxis
  • allergic rhinitis
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • falls
  • hand fracture
  • iliotibial band syndrome
  • open eye injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to avoid exposure to air and moisture. It is also recommended to store it at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Pink oval extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.